Meissner, V H;Jahnen, M;Herkommer, K
[Familial prostate cancer and genetic predisposition].
Urologe A
2021
60
5
567-575

Rexer, H.;Retz, M.;Steiner, T.
Second or Third-Line-Therapy for inoperable, locally advanced or metastatic Renal Cell Carcinoma
Urologe A
2021
60
6
836-837

Rexer, Heidrun;Retz, Margitta;Steiner, Thomas
Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
Aktuelle Urol
2021
52
05
425-426

Rexer, H.;Retz, M.;Hammerer, P.
First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
Urologe A
2021
60
7
987-988

Rexer, Heidrun;Kuebler, Hubert;Retz, Margitta
Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20
Aktuelle Urol
2021
52
03
220-221

Koll, Florestan J;Meisenzahl, Eva;Haller, Bernhard;Maisch, Philipp;Kirchhoff, Florian;Horn, Thomas;Gschwend, Jürgen E;Schmid, Sebastian C
Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC).
Front Surg
2021
8

Appleman, Leonard;Todenhoefer, Tilman;Berry, William;Gurney, Howard;Retz, Margitta;Conter, Henry;Laguerre, Brigitte;Fong, Peter;Ferrario, Cristiano;Gravis, Gwenaelle;Piulats, Josep;Emmenegger, Urban;Shore, Neal;Romano, Emanuela;Mourey, Loic;Li, Xin Tong;Poehlein, Christian;Schloss, Charles;De Bono, Johann;Yu, Evan
KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
J Immunother Cancer
2021
9 Suppl 2
A374-A374

Gschwend, Juergen E.
The Importance of Urine Cytology Reply
Dtsch Arztebl Int
2021
118
31-32
545-545

Meissner, V. H.;Olze, L.;Schiele, S.;Ankerst, D. P.;Jahnen, M.;Gschwend, J. E.;Dinkel, A.;Herkommer, K.
Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study
Eur Urol
2021
79 Suppl 1
S1650-S1650

Jahnen, Matthias;Mynzak, Eike;Meissner, Valentin H;Schiele, Stefan;Schulwitz, Helga;Ankerst, Donna P;Gschwend, Jürgen E;Herkommer, Kathleen;Dinkel, Andreas
Diversity of cancer-related identities in long-term prostate cancer survivors after radical prostatectomy.
BMC Cancer
2021
21
1